Press Release
Akebia Announces Poster Presentations at the Upcoming American Society of Nephrology Kidney Week 2014 Annual Meeting
Poster session details:
Title: Phase
2a Study of AKB-6548, a novel Hypoxia-Inducible Factor
Prolyl-Hydroxylase Inhibitor (HIF-PHI) in Patients with End Stage Renal
Disease (ESRD) Undergoing Hemodialysis (HD) (Poster Board #:INFO25)
Poster
Times:
Location: Exhibit Hall A
Title: Hemodialysis has Minimal
Impact on the Pharmacokinetics of AKB-6548, a Once-Daily Oral Inhibitor
of Hypoxia Inducible Factor Prolyl-Hydroxylases (HIFPHs) for the
Treatment of Anemia Related to Chronic Kidney Disease (CKD) (Poster
Board #:FR-PO952)
Session Title:
Pharmacokinetics/Pharmacodynamics/Pharmacogenomics
Poster Time:
Location: Exhibit Hall A
The clinical posters will be available on Akebia's website (www.akebia.com) in the Media section under the Publications tab.
About AKB-6548
AKB-6548 is a once-daily, oral therapy currently in development for the treatment of anemia related to CKD. AKB-6548 is designed to stabilize HIF, a transcription factor that regulates the expression of genes involved with red blood cell (RBC) production in response to changes in oxygen levels, by inhibiting the hypoxia-inducible factor prolyl hydroxylase (HIF-PH) enzyme. AKB-6548 exploits the same mechanism of action used by the body to naturally adapt to lower oxygen availability associated with a moderate increase in altitude. At higher altitudes, the body responds to lower oxygen availability with increased production of HIF, which coordinates the interdependent processes of iron mobilization and erythropoietin (EPO) production to increase RBC production and, ultimately, improve oxygen delivery.
As a HIF stabilizer with best-in-class potential, AKB-6548 may raise hemoglobin levels and RBC count predictably and sustainably, with a positive safety profile and a dosing regimen that allows for a gradual and controlled titration. Furthermore, AKB-6548 may improve iron mobilization, potentially eliminating intravenous iron administration and reducing the overall need for iron supplementation.
About Anemia Related to CKD
Approximately 30 million people in
About
Investors:
Senior Director, Investor Relations and Corporate
Communications
njones@akebia.com
or
Media:
liz.falcone@fkhealth.com
Source:
News Provided by Acquire Media
Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142
+1 617.871.2098 phone
+1 617.871.2099 fax